Neurocrine Biosciences, Inc. Stock Berne S.E.
Equities
NB3
US64125C1099
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
111.6 CHF | -.--% | -.--% | -.--% |
Sales 2024 * | 2.22B 1.98B | Sales 2025 * | 2.55B 2.27B | Capitalization | 13.63B 12.15B |
---|---|---|---|---|---|
Net income 2024 * | 431M 384M | Net income 2025 * | 675M 602M | EV / Sales 2024 * | 5.24 x |
Net cash position 2024 * | 2B 1.78B | Net cash position 2025 * | 2.81B 2.5B | EV / Sales 2025 * | 4.24 x |
P/E ratio 2024 * |
33.4
x | P/E ratio 2025 * |
21.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+27.39% | 11.61B | |
+106.26% | 10.31B |
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock